Skip to main content
NCBI home page
Genitourinary Medicine logoLink to Genitourinary Medicine
. 1990 Jun;66(3):138–141. doi: 10.1136/sti.66.3.138

HIV-1 P24 antigenaemia does not predict time of survival in AIDS patients.

J W Mulder 1, P Krijnen 1, J Goudsmit 1, J K Schattenkerk 1, P Reiss 1, J M Lange 1
PMCID: PMC1194491  PMID: 2115018

Abstract

The time of survival in 176 AIDS patients was investigated in relation to the presence or absence of HIV-1 p24 antigenaemia at the moment of diagnosis. The median time of survival in p24 antigen positive patients was 12 months, in p24 antigen negative patients it was 13 months; no difference in survival curves was found. Also no difference was found in survival between patients with high and low p24 antigen levels. The median time of survival in patients for whom a diagnosis of AIDS was made in the period before the introduction of zidovudine treatment was 10 months; in patients diagnosed in the period thereafter it was 18 months (p less than 0.005). However, when each period was analysed separately, no difference in survival between p24 antigen positive and negative patients was found. Separate analysis of patients with a diagnosis of Kaposi's sarcoma alone showed similar results. HIV-1 p24 antigenaemia at the moment of diagnosis of AIDS (both in the period before and in the period after the introduction of zidovudine) is not a predictor for time of survival.

Full text

PDF
138

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allain J. P., Laurian Y., Paul D. A., Verroust F., Leuther M., Gazengel C., Senn D., Larrieu M. J., Bosser C. Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia. Potential clinical importance. N Engl J Med. 1987 Oct 29;317(18):1114–1121. doi: 10.1056/NEJM198710293171804. [DOI] [PubMed] [Google Scholar]
  2. Centers for Disease Control (CDC) Revision of the case definition of acquired immunodeficiency syndrome for national reporting--United States. MMWR Morb Mortal Wkly Rep. 1985 Jun 28;34(25):373–375. [PubMed] [Google Scholar]
  3. Creagh-Kirk T., Doi P., Andrews E., Nusinoff-Lehrman S., Tilson H., Hoth D., Barry D. W. Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program. JAMA. 1988 Nov 25;260(20):3009–3015. [PubMed] [Google Scholar]
  4. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  5. Goedert J. J., Kessler C. M., Aledort L. M., Biggar R. J., Andes W. A., White G. C., 2nd, Drummond J. E., Vaidya K., Mann D. L., Eyster M. E. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med. 1989 Oct 26;321(17):1141–1148. doi: 10.1056/NEJM198910263211701. [DOI] [PubMed] [Google Scholar]
  6. Goudsmit J., de Wolf F., Paul D. A., Epstein L. G., Lange J. M., Krone W. J., Speelman H., Wolters E. C., Van der Noordaa J., Oleske J. M. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet. 1986 Jul 26;2(8500):177–180. doi: 10.1016/s0140-6736(86)92485-2. [DOI] [PubMed] [Google Scholar]
  7. Lange J. M., Paul D. A., Huisman H. G., de Wolf F., van den Berg H., Coutinho R. A., Danner S. A., van der Noordaa J., Goudsmit J. Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J (Clin Res Ed) 1986 Dec 6;293(6560):1459–1462. doi: 10.1136/bmj.293.6560.1459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  9. Marasca G., McEvoy M. Length of survival of patients with acquired immune deficiency syndrome in the United Kingdom. Br Med J (Clin Res Ed) 1986 Jun 28;292(6537):1727–1729. doi: 10.1136/bmj.292.6537.1727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Moss A. R., Bacchetti P., Osmond D., Krampf W., Chaisson R. E., Stites D., Wilber J., Allain J. P., Carlson J. Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort. Br Med J (Clin Res Ed) 1988 Mar 12;296(6624):745–750. doi: 10.1136/bmj.296.6624.745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pedersen C., Nielsen C. M., Vestergaard B. F., Gerstoft J., Krogsgaard K., Nielsen J. O. Temporal relation of antigenaemia and loss of antibodies to core antigens to development of clinical disease in HIV infection. Br Med J (Clin Res Ed) 1987 Sep 5;295(6598):567–569. doi: 10.1136/bmj.295.6598.567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Rothenberg R., Woelfel M., Stoneburner R., Milberg J., Parker R., Truman B. Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City. N Engl J Med. 1987 Nov 19;317(21):1297–1302. doi: 10.1056/NEJM198711193172101. [DOI] [PubMed] [Google Scholar]
  13. Rutherford G. W., Schwarcz S. K., Lemp G. F., Barnhart J. L., Rauch K. J., Warner W. L., Piland T. H., Werdegar D. The epidemiology of AIDS-related Kaposi's sarcoma in San Francisco. J Infect Dis. 1989 Mar;159(3):569–572. doi: 10.1093/infdis/159.3.569. [DOI] [PubMed] [Google Scholar]
  14. Volberding P. Treatment of malignant disease in AIDS patients. AIDS. 1988;2 (Suppl 1):S169–S175. doi: 10.1097/00002030-198800001-00025. [DOI] [PubMed] [Google Scholar]
  15. de Wolf F., Goudsmit J., Paul D. A., Lange J. M., Hooijkaas C., Schellekens P., Coutinho R. A., van der Noordaa J. Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia. Br Med J (Clin Res Ed) 1987 Sep 5;295(6598):569–572. doi: 10.1136/bmj.295.6598.569. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. de Wolf F., Lange J. M., Houweling J. T., Coutinho R. A., Schellekens P. T., van der Noordaa J., Goudsmit J. Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. J Infect Dis. 1988 Sep;158(3):615–622. doi: 10.1093/infdis/158.3.615. [DOI] [PubMed] [Google Scholar]
  17. de Wolf F., Lange J. M., Houweling J. T., Mulder J. W., Beemster J., Schellekens P. T., Coutinho R. A., van der Noordaa J., Goudsmit J. Appearance of predictors of disease progression in relation to the development of AIDS. AIDS. 1989 Sep;3(9):563–569. doi: 10.1097/00002030-198909000-00002. [DOI] [PubMed] [Google Scholar]

Articles from Genitourinary Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES